2.2(top 20%)
impact factor
1.2K(top 20%)
papers
67.7K(top 5%)
citations
108(top 5%)
h-index
12.2(top 1%)
extended IF
2.3K
all documents
72.4K
doc citations
153(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and inductionExpert Opinion on Drug Metabolism and Toxicology20061,272
2Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamilyExpert Opinion on Drug Metabolism and Toxicology2008728
3Caco-2 cell permeability assays to measure drug absorptionExpert Opinion on Drug Metabolism and Toxicology2005520
4The Simcyp®Population-based ADME SimulatorExpert Opinion on Drug Metabolism and Toxicology2009484
5The Caco-2 cell monolayer: usefulness and limitationsExpert Opinion on Drug Metabolism and Toxicology2008446
6Zebrafish assays for drug toxicity screeningExpert Opinion on Drug Metabolism and Toxicology2006261
7Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessmentExpert Opinion on Drug Metabolism and Toxicology2008246
8Development of inhibitors of ATP-binding cassette drug transporters – present status and challengesExpert Opinion on Drug Metabolism and Toxicology2008240
9The effect of chronic renal failure on drug metabolism and transportExpert Opinion on Drug Metabolism and Toxicology2008220
10The HepaRG cell line: a uniquein vitrotool for understanding drug metabolism and toxicology in humanExpert Opinion on Drug Metabolism and Toxicology2012216
11Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicineExpert Opinion on Drug Metabolism and Toxicology2018216
12Minimising the potential for metabolic activation in drug discoveryExpert Opinion on Drug Metabolism and Toxicology2005214
13Structure and function of the MRP2 (ABCC2) protein and its role in drug dispositionExpert Opinion on Drug Metabolism and Toxicology2006208
14Pharmacokinetic properties and drug interactions of apigenin, a natural flavoneExpert Opinion on Drug Metabolism and Toxicology2017207
15The rise of PAMPAExpert Opinion on Drug Metabolism and Toxicology2005206
16In silicoADME-Tox modeling: progress and prospectsExpert Opinion on Drug Metabolism and Toxicology2017205
17ABCG2: structure, function and role in drug responseExpert Opinion on Drug Metabolism and Toxicology2008193
18In vitromodels of the human epithelial airway barrier to study the toxic potential of particulate matterExpert Opinion on Drug Metabolism and Toxicology2008188
19Hepatocyte cell lines: their use, scope and limitations in drug metabolism studiesExpert Opinion on Drug Metabolism and Toxicology2006186
20Intestinal efflux transporters and drug absorptionExpert Opinion on Drug Metabolism and Toxicology2008185
21Sertindole: pharmacological and clinical profile and role in the treatment of schizophreniaExpert Opinion on Drug Metabolism and Toxicology2008181
22Is curcumin bioavailability a problem in humans: lessons from clinical trialsExpert Opinion on Drug Metabolism and Toxicology2019179
23The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disordersExpert Opinion on Drug Metabolism and Toxicology2007176
24Whole-body physiologically based pharmacokinetic modelsExpert Opinion on Drug Metabolism and Toxicology2007172
25Sex-specific differences in CYP450 isoforms in humansExpert Opinion on Drug Metabolism and Toxicology2008170
26Ambroxol in the 21st century: pharmacological and clinical updateExpert Opinion on Drug Metabolism and Toxicology2008170
27Luminogenic cytochrome P450 assaysExpert Opinion on Drug Metabolism and Toxicology2006168
28The influence of circadian rhythms on the kinetics of drugs in humansExpert Opinion on Drug Metabolism and Toxicology2008165
29Dexmedetomidine: sedation, analgesia and beyondExpert Opinion on Drug Metabolism and Toxicology2008160
30Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studiesExpert Opinion on Drug Metabolism and Toxicology2011156
31Regulation of drug metabolism and disposition during inflammation and infectionExpert Opinion on Drug Metabolism and Toxicology2005155
32Drug-induced mitochondrial toxicityExpert Opinion on Drug Metabolism and Toxicology2005155
33Pharmacodynamics and pharmacokinetics of inositol(s) in health and diseaseExpert Opinion on Drug Metabolism and Toxicology2016152
34The road map to oral bioavailability: an industrial perspectiveExpert Opinion on Drug Metabolism and Toxicology2006151
35Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactionsExpert Opinion on Drug Metabolism and Toxicology2017151
36Preclinical formulations for discovery and toxicology: physicochemical challengesExpert Opinion on Drug Metabolism and Toxicology2006146
37ABC transporters at the blood–brain barrierExpert Opinion on Drug Metabolism and Toxicology2016145
38Structure – ADME relationship: still a long way to go?Expert Opinion on Drug Metabolism and Toxicology2008142
39Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargineExpert Opinion on Drug Metabolism and Toxicology2015139
40Metabolic activation of carboxylic acidsExpert Opinion on Drug Metabolism and Toxicology2008138
41Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug eliminationExpert Opinion on Drug Metabolism and Toxicology2005136
42Natural polyphenol disposition via coupled metabolic pathwaysExpert Opinion on Drug Metabolism and Toxicology2007136
43Therapeutic drug monitoring of antiepileptic drugs: current status and future prospectsExpert Opinion on Drug Metabolism and Toxicology2020134
44Mitochondrial toxicity assessment in industry – a decade of technology development and insightExpert Opinion on Drug Metabolism and Toxicology2014133
45Role of the aryl hydrocarbon receptor in drug metabolismExpert Opinion on Drug Metabolism and Toxicology2005131
46Precision-cut tissue slices as a tool to predict metabolism of novel drugsExpert Opinion on Drug Metabolism and Toxicology2007130
47From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational toolsExpert Opinion on Drug Metabolism and Toxicology2005129
48Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both?Expert Opinion on Drug Metabolism and Toxicology2008129
49A review of valproate in psychiatric practiceExpert Opinion on Drug Metabolism and Toxicology2009128
50The pregnane X receptor: from bench to bedsideExpert Opinion on Drug Metabolism and Toxicology2008127